According to a post on the FDA’s website, Ionis Pharmaceuticals’ treatment of Pelizaeus-Merzbacher disease was granted orphan designation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis granted orphan status for ALS treatment
- Ionis Pharmaceuticals reports Q2 EPS (60c), consensus (90c)
- Ionis reports second quarter 2023 financial results
- IONS Upcoming Earnings Report: What to Expect?
- Ionis Pharmaceuticals, Novartis enter collaboration
Questions or Comments about the article? Write to editor@tipranks.com